BELL vs. AVO, RUA, POLX, SUN, MHC, MXCT, DEMG, SN, NIOX, and EKF
Should you be buying Belluscura stock or one of its competitors? The main competitors of Belluscura include Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), Polarean Imaging (POLX), Surgical Innovations Group (SUN), MyHealthChecked (MHC), MaxCyte (MXCT), Deltex Medical Group (DEMG), Smith & Nephew (SN), NIOX Group (NIOX), and EKF Diagnostics (EKF). These companies are all part of the "medical devices" industry.
Belluscura vs. Its Competitors
Advanced Oncotherapy (LON:AVO) and Belluscura (LON:BELL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.
Belluscura has higher revenue and earnings than Advanced Oncotherapy. Belluscura is trading at a lower price-to-earnings ratio than Advanced Oncotherapy, indicating that it is currently the more affordable of the two stocks.
Advanced Oncotherapy has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, Belluscura has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
In the previous week, Advanced Oncotherapy's average media sentiment score of 0.00 equaled Belluscura'saverage media sentiment score.
Advanced Oncotherapy has a net margin of 0.00% compared to Belluscura's net margin of -1,030.73%. Advanced Oncotherapy's return on equity of -67.34% beat Belluscura's return on equity.
17.8% of Advanced Oncotherapy shares are held by institutional investors. Comparatively, 0.7% of Belluscura shares are held by institutional investors. 47.5% of Advanced Oncotherapy shares are held by company insiders. Comparatively, 7.1% of Belluscura shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Advanced Oncotherapy beats Belluscura on 6 of the 10 factors compared between the two stocks.
Get Belluscura News Delivered to You Automatically
Sign up to receive the latest news and ratings for BELL and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belluscura Competitors List
Related Companies and Tools
This page (LON:BELL) was last updated on 10/10/2025 by MarketBeat.com Staff
